Toyo Sugar Refining Co Ltd
TSE:2107
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Toyo Sugar Refining Co Ltd
TSE:2107
|
JP |
|
Gakken Holdings Co Ltd
TSE:9470
|
JP |
|
A
|
Allergy Therapeutics PLC
OTC:AGYTF
|
UK |
|
I
|
Insecticides (India) Ltd
NSE:INSECTICID
|
IN |
Balance Sheet
Balance Sheet Decomposition
Toyo Sugar Refining Co Ltd
Toyo Sugar Refining Co Ltd
Balance Sheet
Toyo Sugar Refining Co Ltd
| Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
2 157
|
2 321
|
2 361
|
2 861
|
3 229
|
3 491
|
3 827
|
3 756
|
4 604
|
3 596
|
|
| Cash Equivalents |
2 157
|
2 321
|
2 361
|
2 861
|
3 229
|
3 491
|
3 827
|
3 756
|
4 604
|
3 596
|
|
| Short-Term Investments |
0
|
0
|
10
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
2 239
|
2 031
|
2 328
|
2 338
|
2 117
|
2 188
|
2 114
|
2 379
|
2 933
|
2 656
|
|
| Accounts Receivables |
1 242
|
1 289
|
1 430
|
1 433
|
1 225
|
1 334
|
1 207
|
1 437
|
1 968
|
1 793
|
|
| Other Receivables |
997
|
742
|
898
|
905
|
892
|
854
|
907
|
942
|
965
|
863
|
|
| Inventory |
2 026
|
2 291
|
2 215
|
1 892
|
1 964
|
1 959
|
2 120
|
2 149
|
2 402
|
2 761
|
|
| Other Current Assets |
216
|
194
|
48
|
52
|
48
|
78
|
67
|
112
|
90
|
74
|
|
| Total Current Assets |
6 638
|
6 837
|
6 962
|
7 143
|
7 358
|
7 716
|
8 128
|
8 396
|
10 029
|
9 087
|
|
| PP&E Net |
1 411
|
1 406
|
1 368
|
1 354
|
1 303
|
419
|
411
|
319
|
325
|
353
|
|
| PP&E Gross |
1 411
|
1 406
|
1 368
|
1 354
|
1 303
|
419
|
411
|
319
|
325
|
353
|
|
| Accumulated Depreciation |
1 196
|
1 241
|
1 283
|
1 330
|
1 386
|
1 312
|
1 370
|
1 398
|
1 448
|
1 451
|
|
| Intangible Assets |
34
|
20
|
7
|
24
|
34
|
27
|
21
|
15
|
9
|
9
|
|
| Note Receivable |
0
|
1 866
|
1 755
|
1 689
|
1 757
|
1 792
|
1 847
|
1 842
|
1 902
|
1 583
|
|
| Long-Term Investments |
793
|
802
|
842
|
913
|
917
|
956
|
991
|
1 023
|
1 164
|
1 943
|
|
| Other Long-Term Assets |
369
|
373
|
497
|
363
|
201
|
274
|
282
|
256
|
267
|
281
|
|
| Total Assets |
11 291
N/A
|
11 304
+0%
|
11 431
+1%
|
11 486
+0%
|
11 570
+1%
|
11 184
-3%
|
11 680
+4%
|
11 851
+1%
|
13 696
+16%
|
13 256
-3%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1 175
|
1 171
|
837
|
1 015
|
779
|
773
|
900
|
895
|
1 263
|
1 040
|
|
| Accrued Liabilities |
65
|
66
|
69
|
73
|
72
|
72
|
69
|
73
|
83
|
85
|
|
| Short-Term Debt |
1 500
|
1 410
|
0
|
500
|
500
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
340
|
39
|
1 330
|
0
|
0
|
0
|
6
|
5
|
5
|
5
|
|
| Other Current Liabilities |
497
|
492
|
551
|
610
|
452
|
522
|
525
|
451
|
788
|
896
|
|
| Total Current Liabilities |
3 577
|
3 178
|
2 787
|
2 198
|
1 803
|
1 367
|
1 500
|
1 424
|
2 139
|
2 026
|
|
| Long-Term Debt |
39
|
0
|
0
|
2
|
1
|
0
|
32
|
26
|
20
|
14
|
|
| Deferred Income Tax |
51
|
40
|
0
|
42
|
35
|
36
|
35
|
0
|
0
|
0
|
|
| Other Liabilities |
369
|
397
|
398
|
400
|
396
|
368
|
378
|
400
|
385
|
350
|
|
| Total Liabilities |
4 036
N/A
|
3 615
-10%
|
3 185
-12%
|
2 642
-17%
|
2 235
-15%
|
1 771
-21%
|
1 945
+10%
|
1 850
-5%
|
2 544
+38%
|
2 390
-6%
|
|
| Equity | |||||||||||
| Common Stock |
2 904
|
2 904
|
2 904
|
2 904
|
2 904
|
2 904
|
2 904
|
2 904
|
2 904
|
2 904
|
|
| Retained Earnings |
4 276
|
4 709
|
5 246
|
5 810
|
6 351
|
6 374
|
6 697
|
6 966
|
7 974
|
7 713
|
|
| Unrealized Security Profit/Loss |
0
|
89
|
98
|
119
|
96
|
96
|
93
|
97
|
183
|
160
|
|
| Treasury Stock |
0
|
3
|
3
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
|
| Other Equity |
29
|
10
|
1
|
15
|
12
|
43
|
45
|
38
|
95
|
93
|
|
| Total Equity |
7 255
N/A
|
7 689
+6%
|
8 246
+7%
|
8 844
+7%
|
9 335
+6%
|
9 413
+1%
|
9 735
+3%
|
10 001
+3%
|
11 152
+12%
|
10 866
-3%
|
|
| Total Liabilities & Equity |
11 291
N/A
|
11 304
+0%
|
11 431
+1%
|
11 486
+0%
|
11 570
+1%
|
11 184
-3%
|
11 680
+4%
|
11 851
+1%
|
13 696
+16%
|
13 256
-3%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
|